Safety and Tolerability Study of Multiple Doses of PF-06305591

• Drug: PF-06305591
  
  14 day repeated 20mg BID doses
• Drug: Placebo
  
  14 day repeated BID doses
• Drug: PF-06305591
  
  14 day repeated 80mg BID doses
• Drug: PF-06305591
  
  14 day repeated 40mg BID doses
• Drug: PF-06305591
  
  14 day repeated BID doses
• Drug: PF-06305591
  
  relative bioavailability tablet vs. solution and food effect at 50mg dose

• Experimental: Multiple Dose: Cohort 1
  
  Interventions:
  

  • Drug: PF-06305591
  • Drug: Placebo
• Experimental: Multiple Dose: Cohort 2
  
  Interventions:
  

  • Drug: PF-06305591
  • Drug: Placebo
• Experimental: Multiple Dose: Cohort 3
  
  Interventions:
  

  • Drug: PF-06305591
  • Drug: Placebo
• Experimental: Multiple Dose: Cohort 4
  
  Intervention: Drug: PF-06305591
• Experimental: Relative Bioavilability: Cohort 1
  
  Intervention: Drug: PF-06305591

Inclusion Criteria:

• Healthy male or female subjects of non childbearing potential, between the ages of 21 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG and clinical laboratory tests

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
• Any condition possibly affecting drug absorption (eg, gastrectomy).